Columbia Partners Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Columbia Partners Investment Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$1.51M	Buy	17,806 +9,244	+108%	+$985K	0.59%	52
2018 Q3	$1.47M	Buy	+8,562	New	+$1.29M	0.37%	84
2018 Q2	–	Sell	-4,628	Closed	-$476K	–	193
2018 Q1	$476K	Sell	4,628 -7,213	-61%	-$713K	0.06%	198
2017 Q4	$1.01M	Sell	11,841 -4,806	-29%	-$417K	0.13%	166
2017 Q3	$1.41M	Buy	16,647 +7,217	+77%	+$571K	0.19%	152
2017 Q2	$714K	Sell	9,430 -20,844	-69%	-$1.46M	0.09%	192
2017 Q1	$2M	Sell	30,274 -61,350	-67%	-$4.04M	0.25%	113
2016 Q4	$5.81M	Sell	91,624 -18,465	-17%	-$1.17M	0.52%	64
2016 Q3	$7.01M	Buy	110,089 +38,345	+53%	+$2.82M	0.55%	55
2016 Q2	$5.34M	Sell	71,744 -131	-0.2%	-$9.72K	0.4%	89
2016 Q1	$4.8M	Buy	71,875 +37,303	+108%	+$2.27M	0.34%	113
2015 Q4	$2.34M	Buy	+34,572	New	+$2.13M	0.16%	156

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Columbia Partners Investment Management's LGND Position: Q4 2018 in Review

Columbia Partners Investment Management increased its Ligand Pharmaceuticals (LGND) stake by 108% in Q4 2018, buying an estimated $985K and bringing the position to 17,806 shares worth $1.51M. The position accounts for 0.59% of the portfolio, ranked #52.

Columbia Partners Investment Management first reported a position in LGND in Q4 2015 and has held it in 12 quarters since. The position peaked at $7.01M in Q3 2016. 362 funds tracked by Wall St. Rank hold LGND as of Q4 2018.

Columbia Partners Investment Management held 17,806 shares of Ligand Pharmaceuticals worth $1.51M as of Q4 2018.
Columbia Partners Investment Management bought 9,244 Ligand Pharmaceuticals shares in Q4 2018, an estimated $985K.
Ligand Pharmaceuticals made up 0.59% of Columbia Partners Investment Management's portfolio in Q4 2018, its #52 holding.
Columbia Partners Investment Management first reported a position in Ligand Pharmaceuticals in Q4 2015 and has held it in 12 quarters since.
Columbia Partners Investment Management's Ligand Pharmaceuticals position peaked at $7.01M in Q3 2016.
362 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2018.

Based on Columbia Partners Investment Management's 13F filing for Q4 2018, filed 12 Feb 2019.